Member-only story
Big Pharma Doesn’t Want You to Notice This: The Timing on GLP-1 Drugs is Sus
Although I'm not one to join conspiracy theories, the timing of the new diabetes medications is intriguing given the federal government's $35 monthly cap.
The sudden evolution of new, seemingly miraculous drugs developed to treat diabetes is groundbreaking.
As you probably already know, diabetes is a serious and prevalent condition that affects millions of people worldwide. And while there have been advancements in treatment options for those with diabetes, specifically the development of GLP-1 drugs, I can’t help but feel like something fishy is going on behind closed doors.
Maybe I’ve watched too many episodes of Grey’s Anatomy, or maybe my skepticism towards big pharmaceuticals has grown over the years, but bear with me as I dive into this topic with an open mind and some hard facts.
It seems like big pharmaceutical companies don’t want us to notice one particular aspect surrounding these new drugs—their pricing and timing with government regulations.
The recent developments in the pharmaceutical industry, particularly concerning new diabetes medications known as GLP-1 (glucagon-like peptide-1) drugs, have…
